910132-87-5

Upstream product

• 944327-03-1 4-(2-tert-butoxycarbonyl-ethyl)-3,5-dimethyl-benzoic acid methyl ester 
• 944327-02-0 4-(2-tert-butoxycarbonyl-vinyl)-3,5-dimethyl-benzoic acid methyl ester 
• 944326-88-9 4-(2-tert-butoxycarbonyl-ethyl)-3,5-dimethyl-benzoic acid 
• 10570-67-9 4-iodo-2,6-dimethylphenol 
• 576-26-1 2.6-dimethylphenol 
• 910132-85-3 methyl (E)-4-(3-(tert-butoxy)-3-oxoprop-1-en-1-yl)-3,5-dimethylbenzoate 
• 341006-48-2 methyl 3,5-dimethyl-4-{[(trifluoromethyl)sulfonyl]oxy}benzoate 
• 910132-86-4 tert-butyl (E)-3-(2,6-dimethyl-4-carbamoylphenyl)acrylate 
• 34137-14-9 methyl 4-hydroxy-3,5-dimethylbenzoate 
• 4919-37-3 3,5-dimethyl-4-hydroxybenzoic acid 

Downstream Products

• 910132-88-6 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid 
• 1011264-54-2 3-(4-cyano-2,6-dimethyl-phenyl)-propionic acid tert-butyl ester 
• 1011264-31-5 3-[4-(N-hydroxycarbamimidoyl)-2,6-dimethyl-phenyl]-propionic acid tert-butyl ester 

Relevant academic research and scientific papers

AMINO-PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS

The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, R4, R5, R6 and R7 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDINE COMPOUNDS

The invention relates to pyridine compounds, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

AMINO- PYRIDINE DERIVATIVES AS S1P1 /EDG1 RECEPTOR AGONISTS

The invention relates to novel amino-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opioid antagonists

3-(2,6-Dimethyl-4-carbamoylphenyl)propanoic acid (Dcp), a 2′,6′-dimethyltyrosine analogue containing a carbamoyl group in place of the hydroxyl function and lacking the amino group, was synthesized. The replacement of Tyr1 in an enkephalin analogue and in dynorphin A(1-11)-NH2 with Dcp resulted in the first opioid peptide-derived antagonists that do not contain a phenolic hydroxyl group at the 1-position residue. The cyclic peptide Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH 2 represents a novel, potent μ opioid antagonist.